Literature DB >> 30446822

Mindfulness-based cognitive therapy (MBCT) in patients with obsessive-compulsive disorder (OCD) and residual symptoms after cognitive behavioral therapy (CBT): a randomized controlled trial.

Anne Katrin Külz1, Sarah Landmann2, Barbara Cludius3, Nina Rose2, Thomas Heidenreich4, Lena Jelinek3, Heike Alsleben3, Karina Wahl5, Alexandra Philipsen6,7, Ulrich Voderholzer2,8, Jonathan G Maier2, Steffen Moritz3.   

Abstract

Up to one-third of individuals with obsessive-compulsive disorder (OCD) do not benefit from evidence-based psychotherapy. We examined the efficacy of mindfulness-based cognitive therapy (MBCT) as a complementary treatment option. In a prospective, bicentric, assessor-blinded, randomized, and actively controlled clinical trial, 125 patients with OCD and residual symptoms after cognitive behavioral therapy (CBT) were randomized to either an MBCT group (n = 61) or to a psychoeducational group (OCD-EP; n = 64) as an active control condition. At post-treatment, there was no significant benefit of MBCT over OCD-EP with the Yale-Brown-Obsessive-Compulsive Scale (Y-BOCS) as the primary outcome measure, but with the Obsessive-Compulsive Inventory [OCI-R; F(1, 101) = 5.679, p = .036, effect size η2partial = 0.053]. Moreover, the response rate and the improvement on secondary outcomes such as obsessive beliefs and quality of life was significantly larger in the MBCT group. Non-completion rates were below 10%. At the 6-month follow-up, OC symptoms were further improved in both groups; group differences were no longer significant. Our findings suggest that MBCT, compared to a psychoeducational program, leads to accelerated improvement of self-reported OC symptoms and secondary outcomes, but not of clinician-rated OC symptoms. In the midterm, both interventions yield similar and stable, but small improvements, suggesting that additional treatment options may be necessary.

Entities:  

Keywords:  Mindfulness; Obsessive–compulsive disorder; Psychoeducation; Psychotherapy; Randomized controlled trial

Mesh:

Year:  2018        PMID: 30446822     DOI: 10.1007/s00406-018-0957-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  51 in total

1.  The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group.

Authors:  S M Skevington; M Lotfy; K A O'Connell
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

2.  A short form of the metacognitions questionnaire: properties of the MCQ-30.

Authors:  Adrian Wells; Sam Cartwright-Hatton
Journal:  Behav Res Ther       Date:  2004-04

3.  Screening adults for Asperger Syndrome using the AQ: a preliminary study of its diagnostic validity in clinical practice.

Authors:  M R Woodbury-Smith; J Robinson; S Wheelwright; S Baron-Cohen
Journal:  J Autism Dev Disord       Date:  2005-06

4.  [Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples].

Authors:  C Kühner; C Bürger; F Keller; M Hautzinger
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

5.  Quality of life in obsessive-compulsive disorder before and after treatment.

Authors:  Steffen Moritz; Michael Rufer; Susanne Fricke; Anne Karow; Matthias Morfeld; Lena Jelinek; Dirk Jacobsen
Journal:  Compr Psychiatry       Date:  2005 Nov-Dec       Impact factor: 3.735

6.  Response versus remission in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Jonathan D Huppert; Eva Petkova; Edna B Foa; Michael R Liebowitz
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

7.  The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples.

Authors:  A Osman; C L Bagge; P M Gutierrez; L C Konick; B A Kopper; F X Barrios
Journal:  Assessment       Date:  2001-12

8.  Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment.

Authors:  Melissa M Norberg; John E Calamari; Robyn J Cohen; Bradley C Riemann
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

9.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

10.  The Obsessive-Compulsive Inventory-Revised (OCI-R): validation of the German version in a sample of patients with OCD, anxiety disorders, and depressive disorders.

Authors:  Sascha Gönner; Rainer Leonhart; Willi Ecker
Journal:  J Anxiety Disord       Date:  2007-08-02
View more
  4 in total

1.  Mindfulness-based psychotherapy in patients with obsessive-compulsive disorder: A meta-analytical Study.

Authors:  Antonio Riquelme-Marín; Ana Isabel Rosa-Alcázar; Juan Manuel Ortigosa-Quiles
Journal:  Int J Clin Health Psychol       Date:  2022-07-12

2.  Sexual dysfunction and satisfaction in obsessive compulsive disorder: protocol for a systematic review and meta-analysis.

Authors:  Andrea Pozza; David Veale; Donatella Marazziti; Jaime Delgadillo; Umberto Albert; Giacomo Grassi; Davide Prestia; Davide Dèttore
Journal:  Syst Rev       Date:  2020-01-09

3.  Editorial: Efficacy of Psychological and Psychiatric Treatments and Potential Predictors in Social Anxiety Disorder and Obsessive-Compulsive Disorder.

Authors:  Andrea Pozza
Journal:  Front Psychiatry       Date:  2022-01-21       Impact factor: 4.157

4.  Meditation-based intervention for obsessive-compulsive disorder: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Si Myeong Lee; Hyo-Weon Suh; Hui-Yong Kwak; Jong Woo Kim; Sun-Yong Chung
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.